An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 205894
Company: MYLAN

Products on ANDA 205894

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 205894

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
02/02/2022	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/205894Orig1s000ltr.pdf

Therapeutic Equivalents for ANDA 205894

CYCLOSPORINE

EMULSION;OPHTHALMIC; 0.05%
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	No	AB	207606	APOTEX
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	No	AB	205894	MYLAN
CYCLOSPORINE	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	No	AB	203880	TEVA PHARMS USA INC
RESTASIS	CYCLOSPORINE	0.05%	EMULSION;OPHTHALMIC	Prescription	Yes	AB	050790	ABBVIE

Top